Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus
N. Yu. Nikishina,
E. V. Ermolaeva,
A. A. Mesnyankina,
E. A. Aseeva,
S. K. Soloviev,
B. Sh. Isaeva,
G. M. Koylubaeva,
A. M. Lila https://doi.org/10.14412/1996-7012-2021-6-111-116
Abstract
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by chronic inflammation and damage to vital organs and systems. Despite the great success achieved in the treatment of SLE, glucocorticoids (GC) remain one of the main methods of therapy. The GC toxicity index is an objective method for assessing adverse events associated with their use, and in future studies can be actively used to monitor the safety of various therapy regimens. Wider introduction of this index in the management of patients with SLE will allow to optimize approaches to the selection of GC doses, to consider earlier prescription of biologic disease modifying antirheumatic drugs, before the development of severe irreversible damage.
About the Authors
N. Yu. Nikishina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
E. V. Ermolaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
A. A. Mesnyankina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
S. K. Soloviev
JSC Group of companies MEDSI
Russian Federation
Russian Federation
3A, Gruzinskiy pereulok, Moscow 123056
B. Sh. Isaeva
Asfendiyarov Kazakh National Medical University
Kazakhstan
Kazakhstan
94, Tole Bi street, Almaty 050000
G. M. Koylubaeva
National Center for Cardiology and Therapy named after academician Mirsaid Mirrakhimov under the Ministry of Health of the Kyrgyz Republic
Kyrgyzstan
Kyrgyzstan
3, Togoloka Moldo street, Bishkek 720040
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology;
Department of Rheumatology Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522;
2/1, Barrikadnaya street, Build. 1, Moscow 125993
References
1. Connelly K, Morand EF, Hoi AY. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Intern Med J. 2013 Jun;43(6):618-24. doi: 10.1111/imj.12070.
2. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 Dec 1;365(22):2110-21. doi: 10.1056/NEJMra1100359.
3. Yen EY, Singh RR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis Rheumatol. 2018 Aug;70(8):1251-5. doi: 10.1002/art.40512. Epub 2018 Jun 27.
4. Danza A, Ruiz-Irastorza G, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7): 1145-53. doi: 10.1093/rheumatology/ker410. Epub 2012 Jan 23.
5. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14 Suppl 4(Suppl 4):S4. doi: 10.1186/ar3919.
6. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004 Nov;50(11):3408-17. doi: 10.1002/art.20583.
7. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7): 1145-53. doi: 10.1093/rheumatology/ker410.
8. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131-7. doi: 10.1097/BOR.0b013e3282f51031.
9. Sarnes E, Crofford L, Watson M, et al. Incidence and US costs of corticosteroidassociated adverse events: a systematic literature review. Clin Ther. 2011 Oct;33(10):1413-32. doi: 10.1016/j.clinthera.2011.09.009.
10. Kirschke E, Goswami D, Southworth D, et al. Glucocorticoid receptor function regulated by coordinated action of the Hsp90 and Hsp70 chaperone cycles. Cell. 2014 Jun 19; 157(7):1685-97. doi: 10.1016/j.cell.2014.04.038.
11. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801-8. doi: 10.1002/1529-0131(200008)43:83.0.CO;2-O.
12. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar;36(3): 560-4. doi: 10.3899/jrheum.080828.
13. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003 Sep;30(9):1955-9.
14. Fischer-Betz R, Chehab G, Sander O, et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol. 2012 Nov;39(11):2111-7. doi: 10.3899/jrheum.120537.
15. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum. 2003 Jun; 32(6):370-7. doi: 10.1053/sarh.2002.50003.
16. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004 Jul; 63(7):797-803. doi: 10.1136/ard.2003.014050.
17. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006 Mar;65(3):285-93. doi: 10.1136/ard. 2005.038638.
18. Bel EH, Wenzel SE, Thompson PJ, et al; SIRIUS Investigators. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13): 1189-97. doi: 10.1056/NEJMoa1403291.
19. Fortunet C, Maillefert JF. Comment on: tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice: reply. Rheumatology (Oxford). 2015 Apr; 54(4):751-2. doi: 10.1093/rheumatology/keu468.
20. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008 Mar;20(2):131-7. doi: 10.1097/BOR.0b013e3282f51031.
21. Van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010 Nov;69(11):1913-9. doi: 10.1136/ard.2009.124958.
22. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Nov;52(11):3371-80. doi: 10.1002/art.21421.
23. Nossent JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol. 1998 Apr; 25(4):654-9.
24. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis2015-208916.
25. Santiago T, da Silva JA. Safety of glucocorticoids in rheumatoid arthritis: evidence from recent clinical trials. Neuroimmunomodulation. 2015;22(1-2):57-65. doi: 10.1159/000362726. Epub 2014 Sep 12.
26. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002 Aug; 61(8):718-22. doi: 10.1136/ard.61.8.718.
27. Denburg SD, Carbotte RM, Denburg JA. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatol. 1997 May;24(5): 998-1003.
28. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996 Dec;39(12): 2035-45. doi: 10.1002/art.1780391213.
29. Treharne GJ, Douglas KM, Iwaszko J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007 Dec;5(4):175-90. doi: 10.1002/msc.112.
30. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007 Dec;66(12):1560-7. doi: 10.1136/ard.2007.072157.
31. Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar;76(3): 543-6. doi: 10.1136/annrheumdis2016-210002.
32. Lebedeva VV, Muravyev YuV, Glukhova SI. Evaluation of the modified combined glucocorticoid toxicity index in rheumatoid arthritis: Preliminary data. Nauchno-prakticheskaya revmatologiya. 2020;58(1):26-30. (In Russ.).
Review
For citations:
Nikishina NY, Ermolaeva EV, Mesnyankina AA, Aseeva EA, Soloviev SK, Isaeva BS, Koylubaeva GM, Lila AM. Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(6):111-116. (In Russ.) https://doi.org/10.14412/1996-7012-2021-6-111-116
Views:
641
Email this article 